MIACALCIC

Key points

Unfavourable opinion for reimbursement in the MA indications; i.e.:

• prevention of acute bone loss associated with sudden immobilisation, particularly for subjects with recent osteoporotic fractures;
• treatment of Paget’s disease, only in patients for whom alternative treatments have been ineffective or cannot be used, for example patients with severe kidney disease and
• the treatment of malignant hypercalcaemia.

The clinical benefit is now insufficient (previously it was low) in the indications: Paget’s disease and malignant hypercalcaemia.

The clinical benefit remains insufficient in the indication: prevention of bone loss.

What therapeutic improvement?

Not applicable.

 Role in the care pathway?

The proprietary medicinal product MIACALCIC (salmon calcitonin) no longer has a role in the care pathway in view of the available alternatives.